ÀÌ½Ä ¹ÞÀº Àå±â ÃÖ´ëÇÑ ¿À·¡ À¯Áö½ÃŲ´Ù
| Á¦ ¸ñ | Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. |
|---|---|
| ¹ßÇ¥³âµµ | 2013 |
| ¹ßÇ¥Áö | Nephrol Dial Transplant |
| Á¦ ¸ñ | Outcomes of kidney allograft in recipients with kidney disease of unknown etiology. |
|---|---|
| ¹ßÇ¥³âµµ | 2013 |
| ¹ßÇ¥Áö | Clin Transplant |
| Á¦ ¸ñ | Beneficial effects of pretransplantation microchimerism on rejection-free survival in HLA-haploidentical family donor renal transplantation. |
|---|---|
| ¹ßÇ¥³âµµ | 2013 |
| ¹ßÇ¥Áö | Transplantation |
| Á¦ ¸ñ | Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. |
|---|---|
| ¹ßÇ¥³âµµ | 2013 |
| ¹ßÇ¥Áö | Am J Transplant |
| Á¦ ¸ñ | Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. |
|---|---|
| ¹ßÇ¥³âµµ | 2012 |
| ¹ßÇ¥Áö | Ther Drug Monit |
| Á¦ ¸ñ | Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. |
|---|---|
| ¹ßÇ¥³âµµ | 2013 |
| ¹ßÇ¥Áö | Eur J Clin Pharmacol |
| Á¦ ¸ñ | Cold ischemic time is critical in outcomes of expanded criteria donor renal transplantation |
|---|---|
| ¹ßÇ¥³âµµ | 2013 |
| ¹ßÇ¥Áö | Clin Transplant |

¼¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.
¼¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101